Novo’s New US Chief on Lilly’s Rival Weight-Loss Pill

Novo Nordisk Executive Vice President for US Operations Jamey Millar discusses the US approval of competitor Eli Lilly's obesity pill, the expansion of the GLP-1 category, and the rollout of a new subscription model. He talks with Katie Greifeld for "The Close." (Source: Bloomberg)...

Redirecting to full article...